At a glance
- Company
- Regentis Biomaterials
- Ticker
- NYSE American: RGNT
- Announcement
- Product
Key figures
- Reported pain improvement versus microfracture
- ~100%
- Estimated U.S. market
- ~$3 billion
- Estimated annual U.S. cases
- ~470,000
- Approximate procedure duration
- ~10-minute
- Approximate recovery period
- ~2-week
Products and programs
- GelrinC(R) is positioned as a potential first-in-class, off-the-shelf solution for knee cartilage repair in the U.S., offering a single-step procedure that simplifies treatment and integrates into standard surgical workflows.
- Clinical data show ~100% greater pain improvement versus microfracture, with durable outcomes and MRI-confirmed regeneration of near-native cartilage.
- A single ~10-minute procedure with ~2-week recovery and lower costs versus cell-based therapies supports strong adoption across surgeons, payers, and patients.
- The product targets an estimated ~$3 billion U.S. market with ~470,000 annual cases and no comparable ready-to-use competitor.
- Advancing through a pivotal Phase III trial with CE Mark approval in Europe, the company is approaching key catalysts including commercialization and FDA submission.
Regentis Biomaterials (NYSE American: RGNT) is taking aim at a $3 billion U.S. market with what could be the first true off-the-shelf solution for knee cartilage repair—no cells, no delays, no complexity. Its GelrinC(R) platform delivers faster recovery, stronger outcomes, and lower costs vs. outdated procedures, with clinical data showing ~100% greater pain improvement vs. microfracture. Already CE Mark approved in Europe and advancing through a pivotal U.S. Phase III trial, Regentis is stacked with near-term catalysts that could redefine orthopedic care—and unlock massive upside.
Company Overview
Regentis is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on knee injuries and other orthopedic treatments, Regentis’ Gelrin(TM) platform technology, based on synchronized, degradable…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
Regentis Biomaterials is highlighting GelrinC, its proposed off-the-shelf treatment for knee cartilage repair, as it advances through a pivotal Phase III trial in the United States. The company says the product is a single-step procedure and cites clinical data showing approximately 100% greater pain improvement than microfracture, along with MRI-confirmed cartilage regeneration. The release describes a procedure of about 10 minutes and recovery of roughly two weeks, and says the approach may cost less than cell-based therapies. Regentis estimates a U.S. market of about $3 billion and approximately 470,000 annual cases. GelrinC has CE Mark approval in Europe, according to the release. The company identifies commercialization and an FDA submission as upcoming milestones; no specific timing is provided.
Key takeaways
- Regentis says GelrinC is advancing in a pivotal U.S. Phase III trial.
- The company reports approximately 100% greater pain improvement than microfracture in clinical data.
- GelrinC has CE Mark approval in Europe, according to the release.
- The release cites commercialization and an FDA submission as upcoming milestones.
